The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma

Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer

(2012) Yi Xia et al.   CANCER LETTERS

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

Triptolide: structural modifications, structure–activity relationships, bioactivities, clinical development and mechanisms

(2012) Zhao-Li Zhou et al.   NATURAL PRODUCT REPORTS

A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease

(2012) Peter O. Hofgaard et al.   PLoS One

Prosurvival role of heat shock factor 1 in the pathogenesis of pancreatobiliary tumors

(2011) Vikas Dudeja et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo

(2011) Feng Fang et al.   CANCER

Expression of heat shock proteins in classical Hodgkin lymphoma: correlation with apoptotic pathways and prognostic significance

(2011) Almudena Santón et al.   HISTOPATHOLOGY

Triptolide and its expanding multiple pharmacological functions

(2011) Qiuyan Liu   INTERNATIONAL IMMUNOPHARMACOLOGY

MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML

(2011) B Z Carter et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Total synthesis of novel D-ring-modified triptolide analogues: structure–cytotoxic activity relationship studies on the D-ring of triptolide

(2011) Bing Zhou et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer

(2011) S. Santagata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Implication of Heat Shock Factors in Tumorigenesis: Therapeutical Potential

(2011) Aurelie De Thonel et al.   Cancers

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585

(2010) Thorsten Stühmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma

(2010) E L Davenport et al.   LEUKEMIA

Heat shock factors: integrators of cell stress, development and lifespan

(2010) Malin Åkerfelt et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis

(2010) L Meng et al.   ONCOGENE

Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800

(2009) Thorsten Stühmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

(2009) J.J.E.M. Kitzen et al.   EUROPEAN JOURNAL OF CANCER

Inhibiting the transcription factor HSF1 as an anticancer strategy

(2009) Luke Whitesell et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA

(2009) S. Vispe et al.   MOLECULAR CANCER THERAPEUTICS

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

(2008) A. Zollinger et al.   BLOOD

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

(2008) T Stühmer et al.   LEUKEMIA